SAB Biotherapeutics (SABSW) EBT Margin (2021 - 2025)
Historic EBT Margin for SAB Biotherapeutics (SABSW) over the last 5 years, with Q3 2025 value amounting to 27873.57%.
- SAB Biotherapeutics' EBT Margin changed N/A to 27873.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 68111.45%, marking a year-over-year increase of 711237300.0%. This contributed to the annual value of 3171.7% for FY2024, which is 12872000.0% down from last year.
- According to the latest figures from Q3 2025, SAB Biotherapeutics' EBT Margin is 27873.57%.
- In the past 5 years, SAB Biotherapeutics' EBT Margin ranged from a high of 27873.57% in Q3 2025 and a low of 8669.15% during Q4 2024
- In the last 5 years, SAB Biotherapeutics' EBT Margin had a median value of 150.79% in 2021 and averaged 1589.32%.
- Per our database at Business Quant, SAB Biotherapeutics' EBT Margin tumbled by -79694700bps in 2023 and then surged by 179914300bps in 2025.
- Over the past 5 years, SAB Biotherapeutics' EBT Margin (Quarter) stood at 104.46% in 2021, then crashed by -248bps to 363.23% in 2022, then crashed by -1963bps to 7493.75% in 2023, then dropped by -16bps to 8669.15% in 2024, then soared by 422bps to 27873.57% in 2025.
- Its EBT Margin stands at 27873.57% for Q3 2025, versus 15203.74% for Q2 2025 and 15495.1% for Q1 2025.